HC Wainwright reiterated their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAX – Free Report) in a research report sent to investors on Friday morning, Benzinga reports. They currently have a $14.00 target price on the stock.
Evaxion Biotech A/S Stock Down 3.0 %
EVAX stock opened at $2.59 on Friday. The firm’s fifty day moving average is $2.96 and its 200 day moving average is $3.19. The firm has a market cap of $14.45 million, a PE ratio of -8.93 and a beta of -0.24. Evaxion Biotech A/S has a one year low of $2.26 and a one year high of $13.61. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 2.80.
Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.08. The business had revenue of $3.02 million during the quarter, compared to analyst estimates of $0.19 million. On average, research analysts forecast that Evaxion Biotech A/S will post -0.24 EPS for the current year.
Institutional Investors Weigh In On Evaxion Biotech A/S
About Evaxion Biotech A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.
Further Reading
- Five stocks we like better than Evaxion Biotech A/S
- What Are Trending Stocks? Trending Stocks Explained
- From PACs to Portfolios: Billionaire Bets and Investor Reactions
- Using the MarketBeat Dividend Tax Calculator
- AppLovin Stock Quadruples: What’s Behind the Bullish Sentiment?
- Pros And Cons Of Monthly Dividend Stocks
- Battle of the Retailers: Who Comes Out on Top?
Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.